The United States Patent and Trademark Office (USPTO) has granted U.S. patent 12,122,741, which claims the composition of matter of lead preclinical candidates in Cybin Inc’s (NYSE:CYBN) CYB005 phenethylamines program. The company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for Central Nervous System (CNS) disorders. In addition, the company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT1A and 5-HT2Creceptor agonists. “The granting of this patent in support of our C…
